1. Home
  2. SHOT vs UBX Comparison

SHOT vs UBX Comparison

Compare SHOT & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHOT
  • UBX
  • Stock Information
  • Founded
  • SHOT 2018
  • UBX 2009
  • Country
  • SHOT United States
  • UBX United States
  • Employees
  • SHOT N/A
  • UBX N/A
  • Industry
  • SHOT Biotechnology: Pharmaceutical Preparations
  • UBX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SHOT Health Care
  • UBX Health Care
  • Exchange
  • SHOT Nasdaq
  • UBX Nasdaq
  • Market Cap
  • SHOT 31.4M
  • UBX 38.6M
  • IPO Year
  • SHOT 2020
  • UBX 2018
  • Fundamental
  • Price
  • SHOT $0.47
  • UBX $1.94
  • Analyst Decision
  • SHOT
  • UBX Strong Buy
  • Analyst Count
  • SHOT 0
  • UBX 2
  • Target Price
  • SHOT N/A
  • UBX $7.00
  • AVG Volume (30 Days)
  • SHOT 669.4K
  • UBX 330.9K
  • Earning Date
  • SHOT 03-31-2025
  • UBX 11-04-2024
  • Dividend Yield
  • SHOT N/A
  • UBX N/A
  • EPS Growth
  • SHOT N/A
  • UBX N/A
  • EPS
  • SHOT N/A
  • UBX N/A
  • Revenue
  • SHOT $652,495.00
  • UBX N/A
  • Revenue This Year
  • SHOT N/A
  • UBX N/A
  • Revenue Next Year
  • SHOT N/A
  • UBX $33.62
  • P/E Ratio
  • SHOT N/A
  • UBX N/A
  • Revenue Growth
  • SHOT 68.01
  • UBX N/A
  • 52 Week Low
  • SHOT $0.45
  • UBX $0.94
  • 52 Week High
  • SHOT $3.07
  • UBX $3.10
  • Technical
  • Relative Strength Index (RSI)
  • SHOT 36.56
  • UBX 50.03
  • Support Level
  • SHOT $0.45
  • UBX $1.81
  • Resistance Level
  • SHOT $0.58
  • UBX $2.39
  • Average True Range (ATR)
  • SHOT 0.05
  • UBX 0.27
  • MACD
  • SHOT 0.01
  • UBX -0.06
  • Stochastic Oscillator
  • SHOT 9.45
  • UBX 12.50

About SHOT Safety Shot Inc.

Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

Share on Social Networks: